UBE2O Protein, Human (sf9, His, StrepⅡ)

UBE2O protein acts as a hybrid E2/E3 ubiquitin protein ligase capable of monoubiquitinating target proteins. It negatively regulates TRAF6-mediated NF-kappa-B activation independently of E2 activity. UBE2O Protein, Human (sf9, His, Strep) is the recombinant human-derived UBE2O protein, expressed by sf9 insect cells , with N-Strep, N-8*His labeled tag.

UBE2O, functioning as an E2/E3 hybrid ubiquitin-protein ligase, uniquely exhibits both E2 and E3 ligase activities, facilitating the monoubiquitination of target proteins. Notably, UBE2O plays a dual regulatory role in cellular processes by negatively regulating TRAF6-mediated NF-kappa-B activation independently of its E2 activity and positively influencing BMP7 signaling through the monoubiquitination of SMAD6, thereby impacting adipogenesis. Moreover, UBE2O is involved in modulating the subcellular localization of chromatin-associated proteins, such as BAP1, INO80, and CXXC1, by orchestrating monoubiquitination at specific sites, highlighting its versatile role in cellular trafficking. Additionally, UBE2O participates in the regulation of retrograde transport by collaborating with the TRIM27:MAGEL2 E3 ubiquitin ligase complex, promoting 'Lys-63'-linked ubiquitination of WASHC1 and enhancing endosomal F-actin assembly. These multifaceted activities underscore UBE2O's significance in fine-tuning diverse cellular pathways.

Human

Sf9 insect cells

N-StrepⅡ;N-8*His

Q9C0C9 (A2-K1292)

63893

Partial

ADPAAPTPAAPAPAQAPAPAPEAVPAPAAAPVPAPAPASDSASGPSSDSGPEAGSQRLLFSHDLVSGRYRGSVHFGLVRLIHGEDSDSEGEEEGRGSSGCSEAGGAGHEEGRASPLRRGYVRVQWYPEGVKQHVKETKLKLEDRSVVPRDVVRHMRSTDSQCGTVIDVNIDCAVKLIGTNCIIYPVNSKDLQHIWPFMYGDYIAYDCWLGKVYDLKNQIILKLSNGARCSMNTEDGAKLYDVCPHVSDSGLFFDDSYGFYPGQVLIGPAKIFSSVQWLSGVKPVLSTKSKFRVVVEEVQVVELKVTWITKSFCPGGTDSVSPPPSVITQENLGRVKRLGCFDHAQRQLGERCLYVFPAKVEPAKIAWECPEKNCAQGEGSMAKKVKRLLKKQVVRIMSCSPDTQCSRDHSMEDPDKKGESKTKSEAESASPEETPDGSASPVEMQDEGAEEPHEAGEQLPPFLLKEGRDDRLHSAEQDADDEAADDTDDTSSVTSSASSTTSSQSGSGTSRKKSIPLSIKNLKRKHKRKKNKITRDFKPGDRVAVEVVTTMTSADVMWQDGSVECNIRSNDLFPVHHLDNNEFCPGDFVVDKRVQSCPDPAVYGVVQSGDHIGRTCMVKWFKLRPSGDDVELIGEEEDVSVYDIADHPDFRFRTTDIVIRIGNTEDGAPHKEDEPSVGQVARVDVSSKVEVVWADNSKTIILPQHLYNIESEIEESDYDSVEGSTSGASSDEWEDDSDSWETDNGLVEDEHPKIEEPPIPPLEQPVAPEDKGVVISEEAATAAVQGAVAMAAPMAGLMEKAGKDGPPKSFRELKEAIKILESLKNMTVEQLLTGSPTSPTVEPEKPTREKKFLDDIKKLQENLKKTLDNVAIVEEEKMEAVPDVERKEDKPEGQSPVKAEWPSETPVLCQQCGGKPGVTFTSAKGEVFSVLEFAPSNHSFKKIEFQPPEAKKFFSTVRKEMALLATSLPEGIMVKTFEDRMDLFSALIKGPTRTPYEDGLYLFDIQLPNIYPAVPPHFCYLSQCSGRLNPNLYDNGKVCVSLLGTWIGKGTERWTSKSSLLQVLISIQGLILVNEPYYNEAGFDSDRGLQEGYENSRCYNEMALIRVVQSMTQLVRRPPEVFEQEIRQHFSTGGWRLVNRIESWLETHALLEKAQALPNGVPKASSSPEPPAVAELSDSGQQEPEDGGPAPGEASQGSDSEGGAQGLASASRDHTDQTSETAPDASVPPSVKPKKRRKSYRSFLPEKSGYPDIGFPLFPLSKGFIKSIRGVLTQFRAALLEAGMPECTEDK

Approximately 170 kDa, based on SDS-PAGE under reducing conditions.

≥ 85%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.